A core of kinase-regulated interactomes defines the neoplastic MDSC lineage
Metrics: HTML 1415 views | ?
Maria Gato-Cañas1,2,*, Xabier Martinez de Morentin3,*, Idoia Blanco-Luquin1,2,*, Joaquin Fernandez-Irigoyen3,*, Isabel Zudaire1, Therese Liechtenstein1,2, Hugo Arasanz1,4, Teresa Lozano5, Noelia Casares5, Apirat Chaikuad6, Stefan Knapp6,7, David Guerrero-Setas8, David Escors1,2, Grazyna Kochan9, Enrique Santamaría3
1Immunomodulation group, Navarrabiomed-FMS, IdiSNA, Pamplona, Spain
2Immunomodulation group, Division of Infection and Immunity, University College London, UK
3Proteomics Unit, Navarrabiomed-FMS, Proteored-ISCIII IdiSNA, Pamplona, Spain
4Hospital de Navarra, Department of Oncology, IdiSNA, Pamplona, Spain
5Immunology and Immunotherapy Program, Center for Applied Medical Research, University of Navarra, IdiSNA, Pamplona, Spain
6Structural Genomics Consortium (SGC), University of Oxford, Headington, UK
7Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt, Germany
8Cancer Epigenetics group, Navarrabiomed-FMS, IdiSNA, Pamplona, Spain
9Protein Production Unit, Navarrabiomed-FMS, IdiSNA, Pamplona, Spain
*These authors have contributed equally to this work
David Escors, e-mail: email@example.com
Grazyna Kochan, e-mail: firstname.lastname@example.org
Enrique Santamaría, e-mail: email@example.com
Keywords: MDSC, proteomics, interactomes, kinases, therapeutic targets
Received: May 25, 2015 Accepted: July 13, 2015 Published: July 23, 2015
Myeloid-derived suppressor cells (MDSCs) differentiate from bone marrow precursors, expand in cancer-bearing hosts and accelerate tumor progression. MDSCs have become attractive therapeutic targets, as their elimination strongly enhances anti-neoplastic treatments. Here, immature myeloid dendritic cells (DCs), MDSCs modeling tumor-infiltrating subsets or modeling non-cancerous (NC)-MDSCs were compared by in-depth quantitative proteomics. We found that neoplastic MDSCs differentially expressed a core of kinases which controlled lineage-specific (PI3K-AKT and SRC kinases) and cancer-induced (ERK and PKC kinases) protein interaction networks (interactomes). These kinases contributed to some extent to myeloid differentiation. However, only AKT and ERK specifically drove MDSC differentiation from myeloid precursors. Interfering with AKT and ERK with selective small molecule inhibitors or shRNAs selectively hampered MDSC differentiation and viability. Thus, we provide compelling evidence that MDSCs constitute a distinct myeloid lineage distinguished by a “kinase signature” and well-defined interactomes. Our results define new opportunities for the development of anti-cancer treatments targeting these tumor-promoting immune cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.